New immune cell therapy targets Tough-to-Treat lymphomas
NCT ID NCT04074746
Summary
This study tested a new two-part immunotherapy for patients whose Hodgkin or Non-Hodgkin lymphoma has returned or not responded to other treatments. It combined a special antibody (AFM13) with donated immune cells (NK cells) to help the patient's own immune system find and kill cancer cells. The main goals were to find a safe dose and see if this approach could shrink tumors in patients with CD30-positive cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.